Rosen Law Firm Urges Capricor Investors to Take Action in Fraud Lawsuit

Investors Alert: Join the Capricor Therapeutics Fraud Lawsuit

The Rosen Law Firm, a prominent entity in global investor rights, is alerting shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR) about a significant opportunity to join a class action lawsuit concerning securities fraud. If you purchased shares between December 17, 2025, and July 26, 2026, you could be eligible for compensation with no upfront legal fees through a contingency fee arrangement.

What You Need to Know

A crucial deadline is approaching on September 28, 2026, for investors interested in serving as lead plaintiffs in this case. A lead plaintiff represents the interests of other class members and helps guide the litigation process. The Rosen Law Firm has solid experience and an established track record in securities class actions, making it a valuable ally for investors.

The lawsuit claims that Capricor made materially false statements and failed to disclose important information regarding the approval and efficacy of its product, Deramiocel, a therapeutic agent under review for treating Duchenne muscular dystrophy. The alleged misrepresentations include changes made to the clinical trial data analysis plan without prior approval from regulatory authorities, raising concerns about regulatory compliance and product effectiveness.

Details of the Allegations

To give you a better understanding of the case, here are the main points cited in the lawsuit:
1. Alteration of Clinical Data Analysis Plan: Capricor allegedly altered the pre-specified statistical analysis plan that the FDA had not agreed to, raising questions about the reliability of clinical data presented.
2. Regulatory Risk: There was a significant risk that the FDA could view the clinical results as insufficient evidence of effectiveness, potentially jeopardizing Capricor’s chances of securing regulatory approval.
3. Misleading Statements: Positive assertions made by Capricor regarding its business and operational prospects were allegedly unfounded and misled investors.

The consequences of these alleged misrepresentations resulted in substantial declines in the value of Capricor's shares once the truth about the company's situation came to light, as detailed in the lawsuit.

How to Join the Lawsuit

If you're an investor looking to join the class action against Capricor, you can do so through the Rosen Law Firm's dedicated website or by calling the provided toll-free number for further information. Interested investors should act promptly to protect their rights and interests before the aforementioned deadline.

For additional updates and resources, you can also follow the Rosen Law Firm on social media platforms like LinkedIn and Twitter.

Why Choose Rosen Law Firm?

The Rosen Law Firm has set a precedent in investor rights law, successfully executing the largest securities class action settlement against a Chinese company. The firm has consistently ranked high for its success in this domain, recovering billions for its clients over the years. It is led by Laurence Rosen, recognized among the elite in plaintiff advocacy by reputable legal platforms.

This is an important time for any affected Capricor investors. Engaging legal guidance from experienced counsel ensures you take appropriate steps towards pursuing your claims effectively. Don't miss your chance to seek justice and recovery—act now.

For more information, you can visit their official website at Rosen Law Firm or directly access the case joining page.

Remember, you are not yet represented by counsel until a class certification occurs; hence consider whether to select counsel of your choice or remain an absent class member at this stage.

The Rosen Law Firm encourages investors to meticulously evaluate their options before making decisions. Prior results do not guarantee similar outcomes, but with the right guidance, the potential for recovery is within reach.